Revvity, Inc. (RVTY)
| Market Cap | 11.18B +0.7% |
| Revenue (ttm) | 2.90B +4.8% |
| Net Income | 239.68M -16.4% |
| EPS | 2.09 -10.9% |
| Shares Out | 111.80M |
| PE Ratio | 47.32 |
| Forward PE | 18.07 |
| Dividend | $0.28 (0.28%) |
| Ex-Dividend Date | Jul 17, 2026 |
| Volume | 886,322 |
| Open | 99.13 |
| Previous Close | 98.85 |
| Day's Range | 94.60 - 100.08 |
| 52-Week Range | 81.22 - 118.30 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 107.46 (+7.48%) |
| Earnings Date | May 5, 2026 |
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including... [Read more]
Financial Performance
In 2025, Revvity's revenue was $2.86 billion, an increase of 3.67% compared to the previous year's $2.76 billion. Earnings were $241.20 million, a decrease of -10.79%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $107.46, which is an increase of 7.48% from the latest price.
News
Revvity Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong organic growth and margin outperformance, with robust innovation and a strategic China immunodiagnostics divestiture set to enhance growth and margins. Updated 2026 guidance reflects higher margins, focused capital allocation, and continued operational efficiency.
Revvity Announces Financial Results for the First Quarter of 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing op...
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on Augus...
Revvity Transcript: AGM 2026
The meeting featured board elections, auditor ratification, and approval of executive compensation, all passing with strong majorities. A bylaw amendment for special meetings was adopted, while a shareholder proposal on executive stock retention was rejected.
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: BofA Securities 2026 Health Care Conference Wednesday, May 13, 2026 ...
Revvity to Hold Earnings Call on Tuesday, May 5, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company wil...
Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that stream...
Revvity Transcript: Barclays 28th Annual Global Healthcare Conference
The Signals platform is expanding with AI-driven launches like BioDesign, LabGistics, and Xynthetica, aiming to accelerate research and shift to a consumption-based revenue model. Growth is expected in both software and reagents, with conservative guidance reflecting policy risks, especially in China.
Revvity Transcript: TD Cowen 46th Annual Health Care Conference
Strong Q4 results and robust execution set the stage for 2026, with cost measures driving margin expansion and continued growth in diagnostics, software, and reproductive health. Signals software and new product launches are key to doubling revenue in five years.
Revvity Transcript: 47th Annual Raymond James Institutional Investor Conference
The company has transformed into a focused life sciences and diagnostics leader, emphasizing innovation in software, reagents, and strategic partnerships. AI is expected to drive demand, while operational rigor supports margin expansion and strong cash flow. Guidance for 2026 is conservative, with upside potential if markets recover.
Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026
WALTHAM, Mass.--(BUSINESS WIRE)-- #LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high...
Revvity Analysts Boost Their Forecasts Following Better-Than-Expected Q4 Results
Revvity Inc. (NYSE: RVTY) on Monday reported better-than-expected earnings for the fourth quarter.
Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers
Revvity Inc. (NYSE: RVTY) on Monday reported fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55.
Revvity Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 results exceeded expectations, with strong diagnostics growth and robust share repurchases. 2026 guidance calls for 2%-3% organic growth, margin expansion, and continued innovation, while maintaining a prudent outlook amid market uncertainties.
Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter
Medical equipment maker Revvity handily beat fourth-quarter estimates and forecast 2026 revenue and profit above Wall Street expectations on Monday, betting on continued strength in its diagnostics bu...
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP...
Revvity Transcript: 44th Annual J.P. Morgan Healthcare Conference
Management highlighted a successful transformation to a high-growth, high-margin life sciences and diagnostics company, driven by innovation, AI integration, and strategic partnerships. Operational improvements and disciplined capital allocation support strong margin and EPS growth targets for 2026 and beyond.
Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads.
Wall Street is split on the stock, and the shares are close to the average price target. Something's got to give.
Revvity says it will exceed 2025 profit forecast range
Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and dia...
Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 20...
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly's high-quality predictive models by making L...
Revvity to Present at J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 44th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT. President and Chief Executiv...
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the introduction of its forthcoming Signals Xynthetica™ Models-as-a Service (MaaS) AI offering within the Revvity Signals pl...
Revvity Transcript: Citi Annual Global Healthcare Conference 2025
Activity is increasing in life sciences and instrumentation, with software and AI initiatives driving strong growth. Immunodiagnostics and newborn screening are expanding, while China diagnostics stabilizes post-policy changes. Margin and revenue outlooks remain positive for 2026.
Revvity Transcript: Jefferies London Healthcare Conference 2025
Q3 saw 1% organic growth, with Diagnostics outperforming and Life Sciences flat. Instrumentation demand is rebounding, software is up 25% YTD, and newborn screening continues strong growth. Margin expansion to 28% in 2025 is expected, despite China and tariff headwinds.